PACB Stock - Pacific Biosciences of California, Inc.
Unlock GoAI Insights for PACB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $154.01M | $200.52M | $128.30M | $130.51M | $78.89M |
| Gross Profit | $37.28M | $52.78M | $49.03M | $58.86M | $32.57M |
| Gross Margin | 24.2% | 26.3% | 38.2% | 45.1% | 41.3% |
| Operating Income | $-474,313,000 | $-334,467,000 | $-307,196,000 | $-210,435,000 | $-104,385,000 |
| Net Income | $-309,851,000 | $-306,735,000 | $-314,248,000 | $-181,223,000 | $29.40M |
| Net Margin | -201.2% | -153.0% | -244.9% | -138.9% | 37.3% |
| EPS | $-1.13 | $-1.21 | $-1.40 | $-0.89 | $0.18 |
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 11th 2024 | UBS | Downgrade | Neutral | - |
| June 3rd 2024 | Jefferies | Resumed | Buy | $4 |
| April 22nd 2024 | JP Morgan | Downgrade | Neutral | - |
| April 18th 2024 | Goldman | Downgrade | Neutral | $2.5← $7 |
| December 14th 2023 | Stephens | Initiation | Overweight | $11 |
| December 14th 2023 | Guggenheim | Initiation | Neutral | - |
| December 13th 2023 | Wolfe Research | Initiation | Peer Perform | - |
| November 17th 2023 | UBS | Upgrade | Buy | $10← $13 |
| October 31st 2023 | Cantor Fitzgerald | Upgrade | Overweight | $11 |
| September 28th 2023 | Bernstein | Initiation | Outperform | $11 |
| July 5th 2023 | JP Morgan | Resumed | Overweight | $13 |
| June 30th 2023 | Goldman | Initiation | Buy | $17 |
| May 10th 2023 | Barclays | Initiation | Equal Weight | $14 |
| March 31st 2023 | TD Cowen | Upgrade | Outperform | $15← $13 |
| February 2nd 2023 | UBS | Initiation | Neutral | $13 |
Earnings History & Surprises
PACBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2027 | Feb 9, 2027 | — | — | — | — |
Q4 2026 | Nov 3, 2026 | — | — | — | — |
Q3 2026 | Aug 3, 2026 | — | — | — | — |
Q2 2026 | Apr 7, 2026 | — | — | — | — |
Q1 2026 | Feb 12, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.16 | $-0.12 | +25.0% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.18 | $-0.13 | +27.8% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.20 | $-0.20 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $-0.20 | $-0.17 | +15.0% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-0.24 | $-0.20 | +16.7% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.26 | $-0.26 | 0.0% | = MET |
Q1 2024 | Feb 15, 2024 | $-0.31 | $-0.27 | +12.9% | ✓ BEAT |
Q4 2023 | Oct 30, 2023 | $-0.30 | $-0.27 | +10.0% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-0.34 | $-0.26 | +23.5% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-0.33 | $-0.31 | +6.1% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $-0.35 | $-0.35 | 0.0% | = MET |
Q4 2022 | Nov 7, 2022 | $-0.35 | $-0.32 | +8.6% | ✓ BEAT |
Q3 2022 | Aug 3, 2022 | $-0.34 | $-0.34 | 0.0% | = MET |
Q2 2022 | May 4, 2022 | $-0.32 | $-0.37 | -15.6% | ✗ MISS |
Latest News
Barclays Maintains Equal-Weight on Pacific Biosciences, Raises Price Target to $2
➖ NeutralPiper Sandler Maintains Neutral on Pacific Biosciences, Raises Price Target to $2
➖ NeutralStephens & Co. Maintains Overweight on Pacific Biosciences, Raises Price Target to $2
📈 PositivePacific Biosciences of California shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativePacific Biosciences Q3 Adj. EPS $(0.12) Beats $(0.15) Estimate, Sales $38.441M Miss $40.210M Estimate
➖ NeutralPacBio Announces The Publication Of A New Preprint From The HiFi Solves EMEA Consortium, "HiFi Sequencing Accurately Identifies Clinically Relevant Variants In Paralogous Genes"
📈 PositivePacBio, In Partnership With Berry Genomics, Receives Class III Medical Device Registration From China's NMPA, Enabling High-Accuracy Long-Read Genomic Testing For Thalassemia And Other Complex Genetic Disorders
📈 PositivePacBio Announced Innovations To Its Revio And Vega Platforms To Lower Sequencing Costs, Add New Multiomic Capabilities, And Expand Support For Regulated Research Environments
📈 PositivePacBio's HiFi Technology Selected As Primary Platform For Korean Pangenome Reference Project
📈 PositivePacBio's Revio Systems Chosen By National Institute On Aging Long Life Family Study To Sequence Genomes Of 7,800 Participants In Longevity Study
📈 PositivePacBio Expands Partnership With seqWell To Distribute LongPlex Kit For HiFi Sequencing
📈 PositivePacBio Enters High-Throughput Carrier Screening Market With Expanded PureTarget Kits For Inherited Conditions
📈 PositiveEpiCypher Joins PacBio Compatible Program To Enhance Single-Molecule Chromatin Sequencing With CUTANA Hia5 Enzyme
📈 PositiveFrequently Asked Questions about PACB
What is PACB's current stock price?
What is the analyst price target for PACB?
What sector is Pacific Biosciences of California, Inc. in?
What is PACB's market cap?
Does PACB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PACB for comparison